Snowden Capital Advisors’s Faeth Therapeutics FTH Stock Holding History

Snowden Capital Advisors’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10	Closed	-$1K	–	1918
2021 Q4	$1K	Buy	+10	New	+$1.49K	﹤0.01%	1987

Other funds holding FTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Snowden Capital Advisors's FTH Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Faeth Therapeutics (FTH) in Q1 2022, closing a stake of 10 shares — an estimated $1K sold.

Snowden Capital Advisors first reported a position in FTH in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 42 funds tracked by Wall St. Rank hold FTH as of Q1 2022.

Snowden Capital Advisors reported no remaining Faeth Therapeutics position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 10 Faeth Therapeutics shares in Q1 2022, an estimated $1K.
Snowden Capital Advisors first reported a position in Faeth Therapeutics in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Faeth Therapeutics position peaked at $1K in Q4 2021.
42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.